Prognostic Value of Baseline Thyroglobulin with Complementary FDG PET Stratification in BRAF V600E-Mutant Radioiodine-Refractory Papillary Thyroid Carcinoma Treated with Dabrafenib plus Trametinib (EANM 2026) - Sep 29, 2026 - Abstract #OP-251; Pres time: Oct 18, 2026; 04:45 PM - 06:15 PM; Location: Hall F2; "Dabrafenib plus trametinib demonstrates promising efficacy and a favorable safety profile in BRAF V600E-mutant RAI-R PTC. Our findings highlight that baseline Tg is a robust prognostic marker. Furthermore, integration with FDG PET-derived SUVmax may enhance risk stratification, potentially guiding personalized therapeutic strategies in the era of targeted therapy."
FDG PET • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma • BRAF
|